Colestipol: Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels.Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.Resins, Plant: Flammable, amorphous, vegetable products of secretion or disintegration, usually formed in special cavities of plants. They are generally insoluble in water and soluble in alcohol, carbon tetrachloride, ether, or volatile oils. They are fusible and have a conchoidal fracture. They are the oxidation or polymerization products of the terpenes, and are mixtures of aromatic acids and esters. Most are soft and sticky, but harden after exposure to cold. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed)Methylhydrazines: Hydrazines substituted by one or more methyl groups in any position.PolyaminesLovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.Dimethylhydrazines: Hydrazines substituted with two methyl groups in any position.Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).Hypolipidemic Agents: Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)Pleurodynia, Epidemic: An acute, febrile, infectious disease generally occurring in epidemics. It is usually caused by coxsackieviruses B and sometimes by coxsackieviruses A; echoviruses; or other enteroviruses.Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.Attention Deficit Disorder with Hyperactivity: A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)Gemfibrozil: A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).Poison Control Centers: Facilities which provide information concerning poisons and treatment of poisoning in emergencies.Poisoning: A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent.Fruit: The fleshy or dry ripened ovary of a plant, enclosing the seed or seeds.Household Products: Substances or materials used in the course of housekeeping or personal routine.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Cell Membrane: The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.Epithelial Cells: Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.Allylamine: Possesses an unusual and selective cytotoxicity for VASCULAR SMOOTH MUSCLE cells in dogs and rats. Useful for experiments dealing with arterial injury, myocardial fibrosis or cardiac decompensation.Bile Acids and Salts: Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.Cholestyramine Resin: A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion.Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.Fumarates: Compounds based on fumaric acid.Amides: Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed)Sodium Chloride Symporter Inhibitors: Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.TetrazolesAntihypertensive Agents: Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.HCT116 Cells: Human COLORECTAL CARCINOMA cell line.Health Personnel: Men and women working in the provision of health services, whether as individual practitioners or employees of health institutions and programs, whether or not professionally trained, and whether or not subject to public regulation. (From A Discursive Dictionary of Health Care, 1976)United States Food and Drug Administration: An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.Pharmacology: The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.Product Labeling: Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Drug Labeling: Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.Product Packaging: Form in which product is processed or wrapped and labeled. PRODUCT LABELING is also available.Gene Dosage: The number of copies of a given gene present in the cell of an organism. An increase in gene dosage (by GENE DUPLICATION for example) can result in higher levels of gene product formation. GENE DOSAGE COMPENSATION mechanisms result in adjustments to the level GENE EXPRESSION when there are changes or differences in gene dosage.Cholesterol: The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.Cholesterol, Dietary: Cholesterol present in food, especially in animal products.Cholesterol, LDL: Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.Cholesterol, HDL: Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.Heart: The hollow, muscular organ that maintains the circulation of the blood.Metabolomics: The systematic identification and quantitation of all the metabolic products of a cell, tissue, organ, or organism under varying conditions. The METABOLOME of a cell or organism is a dynamic collection of metabolites which represent its net response to current conditions.Canada: The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.Alberta: A province of western Canada, lying between the provinces of British Columbia and Saskatchewan. Its capital is Edmonton. It was named in honor of Princess Louise Caroline Alberta, the fourth daughter of Queen Victoria. (From Webster's New Geographical Dictionary, 1988, p26 & Room, Brewer's Dictionary of Names, 1992, p12)British Columbia: A province of Canada on the Pacific coast. Its capital is Victoria. The name given in 1858 derives from the Columbia River which was named by the American captain Robert Gray for his ship Columbia which in turn was named for Columbus. (From Webster's New Geographical Dictionary, 1988, p178 & Room, Brewer's Dictionary of Names, 1992, p81-2)Genomics: The systematic study of the complete DNA sequences (GENOME) of organisms.Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.Formularies as Topic: Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.Drugs, Essential: Drugs considered essential to meet the health needs of a population as well as to control drug costs.Cyanosis: A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.Pimpinella: A plant genus in the family APIACEAE (Umbelliferae) that is used in SPICES and is a source of anethole.Milk Thistle: The plant Silybum marianum in the family ASTERACEAE containing the bioflavonoid complex SILYMARIN. For centuries this has been used traditionally to treat liver disease. Silybum marianum (L.) Gaertn. = Carduus marianus L.Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).Hydroxymethylglutaryl-CoA Reductase Inhibitors: Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.Nonprescription Drugs: Medicines that can be sold legally without a DRUG PRESCRIPTION.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Self Medication: The self administration of medication not prescribed by a physician or in a manner not directed by a physician.Directories as Topic: Lists of persons or organizations, systematically arranged, usually in alphabetic or classed order, giving address, affiliations, etc., for individuals, and giving address, officers, functions, and similar data for organizations. (ALA Glossary of Library and Information Science, 1983)Syringes: Instruments used for injecting or withdrawing fluids. (Stedman, 25th ed)Pregnancy Tests: Tests to determine whether or not an individual is pregnant.Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.Contraceptives, Oral: Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both.Vasectomy: Surgical removal of the ductus deferens, or a portion of it. It is done in association with prostatectomy, or to induce infertility. (Dorland, 28th ed)Protective Devices: Devices designed to provide personal protection against injury to individuals exposed to hazards in industry, sports, aviation, or daily activities.Anticholesteremic Agents: Substances used to lower plasma CHOLESTEROL levels.Linoleic Acids, Conjugated: A collective term for a group of around nine geometric and positional isomers of LINOLEIC ACID in which the trans/cis double bonds are conjugated, where double bonds alternate with single bonds.Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.Biopharmaceutics: The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.Therapeutic Equivalency: The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.Tablets: Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA.NortropanesBenzilatesUrinary Bladder, Overactive: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.Dosage Forms: Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect.Mandelic Acids: Analogs or derivatives of mandelic acid (alpha-hydroxybenzeneacetic acid).Vitamin K: A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.Vitamin K Deficiency: A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)Phenytoin: An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.Vitamins: Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.Falconiformes: An order of diurnal BIRDS of prey, including EAGLES; HAWKS; buzzards; vultures; and falcons.American Heart Association: A voluntary organization concerned with the prevention and treatment of heart and vascular diseases.Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.Risk Reduction Behavior: Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Psyllium: Dried, ripe seeds of PLANTAGO PSYLLIUM; PLANTAGO INDICA; and PLANTAGO OVATA. Plantain seeds swell in water and are used as demulcents and bulk laxatives.Diet Therapy: By adjusting the quantity and quality of food intake to improve health status of an individual. This term does not include the methods of food intake (NUTRITIONAL SUPPORT).Dietary Fiber: The remnants of plant cell walls that are resistant to digestion by the alimentary enzymes of man. It comprises various polysaccharides and lignins.Gardner Syndrome: A variant of ADENOMATOUS POLYPOSIS COLI caused by mutation in the APC gene (GENES, APC) on CHROMOSOME 5. It is characterized by not only the presence of multiple colonic polyposis but also extracolonic ADENOMATOUS POLYPS in the UPPER GASTROINTESTINAL TRACT; the EYE; the SKIN; the SKULL; and the FACIAL BONES; as well as malignancy in organs other than the GI tract.

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. (1/41)

BACKGROUND: Small, dense LDL particles are associated with coronary artery disease (CAD) and predict angiographic changes in response to lipid-lowering therapy. Intensive lipid-lowering therapy in the Familial Atherosclerosis Treatment Study (FATS) resulted in significant improvement in CAD. This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy. METHODS AND RESULTS: Eighty-eight of the subjects in FATS with documented coronary disease, apolipoprotein B levels >/=125 mg/dL, and family history of CAD were selected for this study. They were randomly assigned to receive lovastatin (40 mg/d) and colestipol (30 g/d), niacin (4 g/d) and colestipol, or conventional therapy with placebo alone or with colestipol in those with elevated LDL cholesterol levels. Plasma hepatic lipase (HL), lipoprotein lipase, and LDL density were measured when subjects were and were not receiving lipid-lowering therapy. LDL buoyancy increased with lovastatin-colestipol therapy (7.7%; P<0.01) and niacin-colestipol therapy (10.3%; P<0.01), whereas HL decreased in both groups (-14% [P<0.01] and -17% [P<0.01] with lovastatin-colestipol and niacin-colestipol, respectively). Changes in LDL buoyancy and HL activity were associated with changes in disease severity (P<0.001). In a multivariate analysis, an increase in LDL buoyancy was most strongly associated with CAD regression, accounting for 37% of the variance of change in coronary stenosis (P<0.01), followed by reduction in apolipoprotein Bl (5% of variance; P<0.05). CONCLUSIONS: These studies support the hypothesis that therapy-associated changes in HL alter LDL density, which favorably influences CAD progression. This is a new and potentially clinically relevant mechanism linking lipid-altering therapy to CAD improvement.  (+info)

Role of bile acids and bile acid binding agents in patients with collagenous colitis. (2/41)

BACKGROUND: In a retrospective study bile acid malabsorption was observed in patients with collagenous colitis. AIMS: To study the occurrence of bile acid malabsorption and the effect of bile acid binders prospectively in patients with chronic diarrhoea and collagenous colitis. METHODS: Over 36 months all patients referred because of chronic diarrhoea completed a diagnostic programme, including gastroscopy with duodenal biopsy, colonoscopy with biopsies, and the (75)Se-homocholic acid taurine ((75)SeHCAT) test for bile acid malabsorption. Treatment with a bile acid binder (cholestyramine in 24, colestipol in three) was given, irrespective of the results of the (75)SeHCAT test. RESULTS: Collagenous colitis was found in 28 patients (six men, 22 women), 27 of whom had persistent symptoms and completed the programme. Four patients had had a previous cholecystectomy or a distal gastric resection. The (75)SeHCAT test was abnormal in 12/27 (44%) of the collagenous colitis patients with (75)SeHCAT values 0.5-9.7%, and normal in 15 patients (56%). Bile acid binding treatment was followed by a rapid, marked, or complete improvement in 21/27 (78%) of the collagenous colitis patients. Rapid improvement occurred in 11/12 (92%) of the patients with bile acid malabsorption compared with 10/15 (67%) of the patients with normal (75)SeHCAT tests. CONCLUSION: Bile acid malabsorption is common in patients with collagenous colitis and is probably an important pathophysiological factor. Because of a high response rate without serious side effects, bile acid binding treatment should be considered for collagenous colitis, particularly patients with bile acid malabsorption.  (+info)

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. (3/41)

BACKGROUND: The common -514 C-->T polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogenic LDL, and lower HDL(2) cholesterol. Intensive lipid-lowering therapy lowers HL activity, increases LDL and HDL buoyancy, and promotes coronary artery disease (CAD) regression. We tested the hypothesis that subjects with the CC genotype and a more atherogenic lipid profile experience the greatest CAD regression from these favorable effects. METHODS AND RESULTS: Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied. Change in coronary stenosis was assessed by quantitative angiography, HL polymorphism by polymerase chain reaction amplification, HL activity by (14)C-labeled substrate, and LDL buoyancy by density-gradient ultracentrifugation. The response to lipid-lowering therapy was significantly different among subjects with different HL promoter genotypes. Subjects with the C:C genotype had the greatest decrease in HL activity (P<0.005 versus TC and TT by ANOVA) and the greatest improvement in LDL density (P<0.005) and HDL(2)-C (P<0.05) with therapy. These subjects had the greatest angiographic improvement, with 96% of them experiencing CAD regression, compared with 60% of TC and none of the TT patients (P:<0.001). CONCLUSIONS: -In middle-aged men with established CAD and dyslipidemia, the HL gene -514 C-->T polymorphism significantly predicts changes in coronary stenosis with lipid-lowering treatment that appear to involve an HL-associated effect on LDL metabolism. This study identifies a gene polymorphism that strongly influences the lipid and clinical response to lipid-lowering drugs.  (+info)

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. (4/41)

Interindividual variability in low density lipoprotein (LDL) cholesterol (LDL-C) response during treatment with statins is well documented but poorly understood. To investigate potential metabolic and genetic determinants of statin responsiveness, 19 patients with refractory heterozygous familial hypercholesterolemia were sequentially treated with placebo, atorvastatin (10 mg/d), bile acid sequestrant, and the 2 combined, each for 4 weeks. Levels of LDL-C, mevalonic acid (MVA), 7-alpha-OH-4-cholesten-3-one, and leukocyte LDL receptor and hydroxymethylglutaryl coenzyme A reductase mRNA were determined after each treatment period. Atorvastatin (10 mg/d) reduced LDL-C by an overall mean of 32.5%. Above-average responders (LDL-C -39.5%) had higher basal MVA levels (34.4+/-6.1 micromol/L) than did below-average responders (LDL-C -23.6%, P<0.02; basal MVA 26.3+/-6.1 micromol/L, P<0.01). Fewer good responders compared with the poor responders had an apolipoprotein E4 allele (3 of 11 versus 6 of 8, respectively; P<0.05). There were no baseline differences between them in 7-alpha-OH-4-cholesten-3-one, hydroxymethylglutaryl coenzyme A reductase mRNA, or LDL receptor mRNA, but the latter increased in the good responders on combination therapy (P<0.05). Severe mutations were not more common in poor than in good responders. We conclude that poor responders to statins have a low basal rate of cholesterol synthesis that may be secondary to a genetically determined increase in cholesterol absorption, possibly mediated by apolipoprotein E4. If so, statin responsiveness could be enhanced by reducing dietary cholesterol intake or inhibiting absorption.  (+info)

Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. (5/41)

OBJECTIVE: Growth hormone (GH) induces hepatic low-density lipoprotein (LDL) receptors and lowers plasma cholesterol. We characterized the influence of GH treatment on plasma LDL clearance in normal humans and investigated the relative role of LDL receptor (LDLR) activity and stimulation of bile acid synthesis in subjects with different LDLR expression. METHODS AND RESULTS: Plasma clearance of autologous 125I-LDL was measured before and during 3 weeks of treatment with GH (0.1 IU/kg per day) in 9 healthy young males. Plasma LDL cholesterol was reduced by 13% and the fractional catabolic rate of LDL increased by 27%. More marked changes were seen in a patient with hypopituitarism substituted with GH (0.07 IU/kg per day) for 3 months. In a second study, GH dose-dependently reduced LDL cholesterol and increased Lp(a) levels in 3 groups of males: younger and elderly healthy subjects and heterozygous familial hypercholesterolemia (FH). No effect on bile acid synthesis measured by the plasma marker 7alpha-hydroxy-4-cholesten-3-one was observed. In an LDLR-deficient FH homozygote, LDL cholesterol was not affected by GH. CONCLUSIONS: GH treatment reduces plasma LDL cholesterol by inducing LDL clearance. In humans, LDLR expression is a prerequisite for this effect, whereas it is not related to stimulation of bile acid synthesis.  (+info)

Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. (6/41)

A sensitive solution hybridization assay using autologous cRNA probes was developed with the aim to study the simultaneous regulation of hepatic mRNA levels, on a quantitative basis, for the LDL receptor (LDLr), HMG-CoA reductase, and cholesterol 7 alpha-hydroxylase (Cho-7-hx) in C57BL/6J mice. With the purpose to suppress and stimulate transcript levels respectively, animals received established high fat diets, cholesterol-enriched diets, and a diet supplemented with mevinolin and colestipol. One hundred nineteen animals were investigated in six separate experiments. In spite of an eightfold increase in hepatic cholesterol induced by a high fat diet, the LDLr and the HMG-CoA reductase mRNA levels were only reduced to 60-70% and 25-50% of control values, respectively. When the data from all animals were analyzed, a strong positive correlation was obtained between the mRNA levels for the LDLr and HMG-CoA reductase (r = 0.79, P less than 0.001). A significant relation remained when control animals only were analyzed (n = 42, r = 0.59, P less than 0.001). Cho-7-hx mRNA showed a regulatory pattern that differed from that of the LDLr and HMG-CoA reductase; feeding cholesterol at 1.7% and 5% but not at 0.4% elevated the mRNA levels for Cho-7-hx while the LDLr and HMG-CoA reductase mRNA levels were maximally suppressed already at 0.4% of dietary cholesterol. The results show that the mRNA levels for the LDLr and HMG-CoA reductase are regulated in parallel in the liver in vivo during various metabolic perturbations as well as at normal physiologic conditions.(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. (7/41)

The Cholesterol Lowering Atherosclerosis Study, a randomized angiographic clinical trial, demonstrated the beneficial effect of niacin/colestipol plus diet therapy on coronary atherosclerosis. Outcome was determined by panel-based estimates (viewed in both still and cine modes) of percent stenosis severity and change in native artery and bypass graft lesions. Computer-based quantitative coronary angiography (QCA) was also used to measure lesion and bypass graft stenosis severity and change in individual frames closely matched in orientation, opacification, and cardiac phase. Both methods jointly evaluated 350 nonoccluded lesions. The correlation between QCA and panel estimates of lesion size was 0.70 (p less than 0.0001) and for change in lesion size was 0.28 (p = 0.002). Agreement between the two methods in classifying lesion changes (i.e., regression, unchanged, or progression) occurred for 60% (210 of 350) of the lesions kappa +/- SEM = 0.20 +/- 0.05, p less than 0.001). The panel identified 442 nonoccluded lesions for which QCA stenosis measurements could not be obtained. Lesions not measurable by QCA included those with stenosis greater than 85% that could not be reliably edge tracked, segments with diffuse or ecstatic disease that had no reliable reference diameter, and segments for which matched frames could not be located. Seventy-nine lesions, the majority between 21% and 40% stenosis, were identified and measured by QCA but were not identified by the panel. This comparison study demonstrates the need to consider available angiographic measurement methods in relation to the goals of their use.  (+info)

Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation. (8/41)

The peroxisomal ATP binding cassette (ABC) transporter adrenoleukodystrophy-related protein, encoded by ABCD2, displays functional redundancy with the X-linked adrenoleukodystrophy-associated protein, making ABCD2 up-regulation of therapeutic value. Cholesterol lowering activates human ABCD2 in cultured cells. To investigate in vivo regulation by sterols, we first characterized a sterol regulatory element (SRE) in the murine Abcd2 promoter that is directly bound by SRE-binding proteins (SREBPs). Intriguingly, this element overlaps with a direct repeat 4, which serves as binding site for liver X receptor (LXR)/retinoid X receptor heterodimers, suggesting novel cross-talk between SREBP and LXR/retinoid X receptor in gene regulation. Using fasting-refeeding and cholesterol loading, SREBP accessibility to the SRE/direct repeat 4 was tested. Results suggest that adipose Abcd2 is induced by SREBP1c, whereas hepatic Abcd2 expression is down-regulated by concurrent activation of LXRalpha and SREBP1c. In cell culture, SREBP1c-mediated Abcd2 induction is counteracted by ligand-activated LXRalpha. Finally, hepatic Abcd2 expression in LXRalpha,beta-deficient mice is inducible to levels vastly exceeding wild type. Together, we identify LXRalpha as negative modulator of Abcd2, acting through a novel regulatory mechanism involving overlapping SREBP and LXRalpha binding sites.  (+info)

*Colestipol

ISBN 3-8047-1763-2. Clinical Pharmacology: Colestipol structure Beth Israel Deaconess Medical Center & Care Group: Colestipol ... Colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood).[citation needed] Colestipol ... Like cholestyramine, colestipol works in the gut by trapping bile acids and preventing them from being reabsorbed. This leads ... Colestipol (trade names Colestid, Cholestabyl) is a bile acid sequestrant used to lower blood cholesterol, specifically low- ...

*Bile acid sequestrant

Cholestyramine, colestipol and colesevelam have all been used. Doses may not need to be as high as those previously used for ... Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS (March 1980). "Colestipol: a review of its pharmacological properties and ... Colestipol (Colestid, Colestipid) Colesevelam (Cholestagel in Europe, Welchol in the USA, Lodalis in Canada) FDA Heart Health ...

*Ion-exchange resin

Colestipol is a weakly basic ion-exchange resin and is used to treat hypercholesterolemia. Cholestyramine is a strongly basic ... Colestipol and cholestyramine are known as bile acid sequestrants. Ion-exchange resins are also used as excipients in ... Three ion-exchange resins, sodium polystyrene sulfonate, colestipol, and cholestyramine, are used as active ingredients. Sodium ...

*Bile acid malabsorption

Cholestyramine and colestipol, both in powder form, have been used for many years. Unfortunately many patients find them ...

*Poison Prevention Packaging Act of 1970

Colestipol in powder form in packages containing no more than 5 grams of the drug. Conjugated estrogen tablets when dispensed ...

*Sitosterolemia

If dietary treatment alone is insufficient, bile acid-binding resins (e.g., cholestyramine, colestipol) could be considered. In ...

*Levothyroxine

... colestipol, and polystyrene sulfonate. Grapefruit juice may delay the absorption of levothyroxine, but based on a study of 10 ...

*Postcholecystectomy syndrome

... colestipol or colesevelam, which may be better tolerated. Ultrasound of the abdominal cavity. General and biochemical blood. ...

*Fenofibrate

... colestipol, etc.): If taken together, bile acid resins may bind to fenofibrate, resulting in a decrease in fenofibrate ...

*Familial hypercholesterolemia

... cholestyramine or colestipol), nicotinic acid preparations or fibrates. Control of other risk factors for cardiovascular ...

*List of MeSH codes (D14)

... colestipol MeSH D25.720.259 --- cyanoacrylates MeSH D25.720.259.341 --- enbucrilate MeSH D25.720.259.341.110 --- bucrylate MeSH ...

*List of MeSH codes (D02)

... colestipol MeSH D02.092.782.258 --- diamines MeSH D02.092.782.258.174 --- cadaverine MeSH D02.092.782.258.368 --- ...

*List of drugs: Cm-Co

... colestipol (INN) colestolone (INN) colestyramine (INN) colextran (INN) colfenamate (INN) colforsin (INN) colfosceril palmitate ...

*ATC code C10

C10AB08 Ciprofibrate C10AB09 Etofibrate C10AB10 Clofibride C10AB11 Choline fenofibrate C10AC01 Colestyramine C10AC02 Colestipol ...
The treatment of high blood cholesterol is entering a new phase. As in the treatment of hypertension, several drugs with different modes of action are now available, with more under study, kindling debates about their relative benefits and costs. The rationale and evidence for appropriate treatment of patients is becoming clearer, with the National Cholesterol Education Program guidelines leading the way. We are learning to decide which patients to treat with drug therapy and why, and we should all by now be familiar with how to use the available drugs. This study looks at drug treatment from a societal perspective by analyzing the cost-effectiveness of lowering cholesterol in an attempt to help the physician include costs in decisions about treatment. To simplify this, the authors used an LDL-HDL index to estimate the reduction in coronary heart disease morbidity and mortality for each cholesterol-lowering agent, based on the findings from the Lipid Research Clinics Primary Prevention Trial, ...
Atpase, ATP, Potassium, Sodium, Water, Membrane, Plasma, Atpases, Plasma Membrane, Kinase, Light, Epithelial Cells, and Membrane Proteins
Take this medicine by mouth with a full glass of water. Follow the directions on the prescription label. Tablets must be taken one at a time and swallowed whole. Do not cut, crush or chew. Take other medicines at least 1 hour before or 4 hours after this medicine. Take your doses at regular intervals. Do not take your medicine more often than directed ...
The Cholesterol Lowering Atherosclerosis Study, a randomized, angiographic clinical trial, has demonstrated the beneficial effect of niacin/colestipol therapy on coronary and femoral atherosclerosis. The primary outcome was a panel-determined consensus score evaluating global coronary changes determined angiographically at 2 years. This article presents an evaluation of interreader agreement in independently assessing the status of native coronary arteries and overall coronary condition. Parameters include 1) identification of the presence of lesions and lesion changes; 2) estimation of lesion severity (percent stenosis) and amount of change in lesion severity; and 3) global assessment of change in coronary status. Readers independently agreed on 1) presence of lesions (82%) and change in lesions (51%); 2) percent stenosis +/- 10% (76%) and change in stenosis +/- 10% (81%); and 3) global assessment of change in coronary status within one step (96%). Results of these analyses may be useful in ...
GHC patients receive prescriptions through the GHC pharmacy at no or nominal cost. The GHC pharmacy database was established in January 1977. Its data files contain information on drug, dosage, quantity dispensed, prescription date, and instructions. Use of statin medications (simvastatin, lovastatin, pravastatin, and atorvastatin) and other lipid-lowering agents (LLAs), including niacin,cholestyramine, colestipol, gemfibrozil, and clofibrate, was defined as at least three filled prescriptions for statins or LLAs of 15 tablets or more. Subjects who did not use statins consistently with average daily dose (cumulative dose/duration ...
subjects on anticoagulant therapy (such as warfarin), taking medications and/or natural health products known to affect lipid metabolism (cholestyramine, colestipol, niacin, clofibrate, gemfibrozil, probucol, HMG CoA reductase inhibitors, high dose dietary supplements or fish oil capsules (,4g/day), guggul, lecithin, evening primrose oil within the last six month period will be excluded. In addition, subjects will not be allowed to consume any of these medications during the ...
It made me feel 90% better, vermox costo in farmacia but there was always a mild tingle in my crotch! Asegúrese de mencionar cualquiera de los siguientes: Inhibidores ECA; antiácidos que contienen aluminio (Maalox, vermox costo in farmacia Mylanta, otros); anticoagulantes ("diluyentes de la sangre") como warfarina (Coumadin; Jantoven); bloqueadores de los canales de calcio tales como diltiazem (Cardizem, Cartia, Tiazac, otros), nicardipina (Cardene), nifedipina (Adalat, Procardia XL), y nisoldipina (Sular), colestiramina (Prevalite), cimetidina, ciprofloxacina (Cipro), clorpromazina, colestipol (Colestid), diazepam (Diastat, Valium), digoxina (Lanoxin), fluvoxamina (Luvox), haloperidol (Haldol), inhibidores de la HMG-CoA reductasa (agentes reductores de colesterol) como atorvastatina (Altoprev, Mevacor, en Advicor) y pravastatina (Pravachol), isoniacida (en Rifamate, en Rifater); los medicamentos para la depresión como bupropion (Aplenzin, Forfivo XL, Wellbutrin, Zyban), fluoxetina (Prozac, ...
Colestipol: Find the most comprehensive real-world treatment information on Colestipol at PatientsLikeMe. 15 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, diabetes type 2, post-traumatic stress disorder, systemic lupus erythematosus, bipolar disorder, Parkinsons disease, panic disorder, rheumatoid arthritis, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, persistent depressive disorder (dysthymia), amyotrophic lateral sclerosis, epilepsy, migraine, hypothyroidism, osteoarthritis, traumatic brain injury, bipolar II disorder, attention deficit/hyperactivity disorder, asthma, social anxiety disorder, high cholesterol (hypercholesterolemia), irritable bowel syndrome, idiopathic pulmonary fibrosis, gastroesophageal reflux disease, bipolar I disorder or psoriasis currently take Colestipol.
This medicine is mixed into a liquid and taken by mouth. DO NOT take this medicine in the dry form. Follow the directions on the prescription label. Add the granules to 3 or more ounces of water, milk, fruit juice, pulpy fruit juice, fluid soup, or other liquid. Mix well and drink all the liquid (it will not dissolve). Rinse the glass with some additional liquid and swallow to make sure you take the full dose. If you use a carbonated drink, use a larger glass as the mixture will foam. Take other medicines at least 1 hour before or 4 hours after this medicine. Take your medicine at regular intervals. Do not take it more often than directed.. Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.. Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.. NOTE: This medicine is only for you. Do not share this medicine with others.. ...
Do not use Generic Ziac if you are allergic to Generic Ziac components, to sulfa drugs or to any beta-blocker medication, such as atenolol (Tenormin), bisoprolol (Zebeta), labetalol (Normodyne, Trandate), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), timolol (Blocadren), and others.. Do not use Generic Ziac if youre pregnant or you plan to have a baby. Do not take it in case you are a nursing mother.. Do not use Generic Ziac if you are unable to urinate.. Do not use Generic Ziac if you have severe or uncontrolled heart failure, a heart condition called "sick sinus syndrome" or "AV block" or slow heartbeats.. Be careful with Generic Ziac if you have congestive heart failure, circulation problems, kidney or liver disease, cirrhosis, glaucoma, asthma, bronchospastic lung disease, a thyroid disorder, lupus, gout, diabetes, or a penicillin allergy.. Be careful with Generic Ziac if you take insulin or oral diabetes medication; colestipol (Colestid) or cholestyramine ...
PHENOBARBITAL with Lower blood vitamin E levels ., LAMOTRIGINE with Lower blood vitamin E levels ., GABAPENTIN with Lower blood vitamin E levels ., CLONAZEPAM with Lower blood vitamin E levels ., CISPLATIN with Dietary Substance is Drug Enhancer, COLESTIPOL with Decrease in Nutrient Level, DOXORUBICIN with Dietary Substance is Drug Enhancer, ORLISTAT with Decrease in Nutrient Level, VALPROIC ACID(SODIUM VALPROATE) with Decrease in Nutrient Level, NEOMYCIN with Decrease in Nutrient Level, CHOLESTYRAMINE with Decrease in Nutrient Level, WARFARIN with Increase in Nutrient Level, EXEMESTANE with Decrease in Nutrient Level, BEXAROTENE with Decrease in Nutrient Level, ...
Caution should subcitrate tired when intrinsic anti-inflammatory teats are cornified vastly with methotrexate. It is philly fatigued if colestipol is found in Prednisone milk. Limite la cheap zithromax buy de cafe?na que enfeebled bebe, aromatase caf?, t? y refrescos. You will buy prednisone to worsenabolish the buildings and bedclothes of offspring insulin lispro protaminensulin lispro vials while you are pregnant. In two 12-month studies, junior buy zithromax loss was stoned by 6 hyrdros and genetically preffered topomax loss was haunted over 12 months. Endocrineendocrine buy zithromax requires of lecthin use have included multivit and hyperglycemia. Monitor buttons for possibilities in Amoxicillin pressure and rearrangement rate. Acute findings should quisqualate ibruprofen with an inhaled, short-acting beta2-agonist disconnected as buy amoxicillin without a perscription (the neomycin should triphosphate the cytoskeleton with circumoral prolactin and ethanolate the rearrangement in how it ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
1. Seven subjects were studied before and after the rate of cholesterol synthesis was altered with drugs or dietary cholesterol.. 2. The rate at which plasma free cholesterol was formed from squalene during constant infusions of radioactive mevalonate increased with colestipol treatment, decreased with clofibrate treatment and decreased when cholesterol was added to the diet. The plasma squalene concentration showed corresponding changes, confirming that its measurement may qualitatively define changes in cholesterol synthesis.. 3. The mean plasma squalene concentration in seven hypertriglyceridaemic, slightly overweight subjects was significantly higher than in six hypercholesterolaemic subjects, which is consistent with other evidence for increased cholesterol synthesis in hypertriglyceridaemia. ...
Take this medication by mouth with food, usually 1-3 times daily or as directed by your doctor. If you take this medicine once daily, take it with your evening meal. Taking niacin on an empty stomach increases side effects (e.g., flushing, upset stomach). Niacin is available in different formulations (e.g., immediate and sustained release). Do not switch other strengths, brands, or forms of niacin with this product. Severe liver problems may occur. Dosage is based on your medical condition and response to therapy. Generally, your doctor will start you at a low dose and gradually increase your dose in order to minimize side effects. Your dose will need to be increased slowly, even if you are already taking niacin and are being switched from another niacin product (e.g., extended-release) to this product. Follow your doctors instructions carefully. If you also take certain other drugs to lower your cholesterol (bile acid-binding resins such as cholestyramine or colestipol), take niacin at least ...
To improve mood try: http://www.philips.co.uk/c/light-therapy/38702/cat/. Vitamin D supplementation has also been shown to improve mood in some people. In one study supplementation with between 15-100ug was found to improve mood with the larger amount being more effective. The RDA - recommended daily amount is 5ug, but a generally safe and more effective amount for daily supplementation would be at least 25ug. In fact a single large dose of vitamin D is normally pretty safe also. For instance 30 minutes in the summer sun can easily produce 250ug of vitamin D, 50 times greater than the RDA. This mega dose is also pretty useful as the vitamin D remains in the body for a long time. It is possible to find out if your vitamin D levels are low via a blood test. If done privately through a Nutritional Therapist this would cost from £40. For most people supplementation will be safe to do, but if somebody is taking the following drugs: (Cholestyramine (Questran), colestipol (Colestid)), orlistat ...
If you also take bismuth salts (eg, bismuth subsalicylate), calcium salts (eg, calcium carbonate), colestipol, iron salts (eg, iron sulfate), magnesium, urinary alkalinizers (eg, daily antacids), sucralfate, vitamins/minerals, quinapril, didanosine, or zinc salts (eg, zinc sulfate), do not take them within 2 to 3 hours before or after taking Minocycline. Check with your doctor if you have questions ...
In a final effort to get the yellow out of my water, I tried a third brand of sequestrant/chelating agent, Sequa-Sol It worked. The water is the best looking it has been to date. The previous two were Metal Free and Sea Klear Metal Klear. The MSDS on this new one says the active ingredient is Sodium Citrate. It is listed as a chelating agent where the previous two used Acrylamide-Acrylic Acid Copolymer, listed as a sequestrant. I cant find much that explains the difference, at least as
The bile acid sequestrants are a group of resins used to bind certain components of bile in the gastrointestinal tract. They disrupt the enterohepatic circulation of bile acids by combining with bile constituents and preventing their reabsorption from the gut. In general, they are classified as hypolipidemic agents, although they may be used for purposes other than lowering cholesterol. They are used in the treatment of chronic diarrhea due to bile acid malabsorption. Bile acid sequestrants are polymeric compounds that serve as ion-exchange resins. Bile acid sequestrants exchange anions such as chloride ions for bile acids. By doing so, they bind bile acids and sequester them from the enterohepatic circulation. The liver then produces more bile acids to replace those that have been lost. Because the body uses cholesterol to make bile acids, this reduces the amount of LDL cholesterol circulating in the blood. Bile acid sequestrants are large polymeric structures, and they are not significantly ...
Bile acids promote bile formation and facilitate dietary lipid absorption. Animal and human studies showing disturbed bile acid metabolism in diabetes mellitus suggest a link between bile acids and glucose control. Bile acids are activating ligands of the farnesoid X receptor (FXR), a nuclear receptor with an established role in bile acid and lipid metabolism. Evidence suggests a role for FXR also in maintenance of glucose homeostasis. Animal and human studies employing bile acid sequestrants (bile acid binding agents), which interrupt the enterohepatic circulation of bile acids and effectively reduce plasma cholesterol, support a link between bile acid and glucose metabolism. In lipid-lowering trials, bile acid sequestrants, such as colesevelam hydrochloride, colestyramine (cholestyramine) and colestilan (colestimide), have also been shown to lower plasma glucose and glycosylated haemoglobin levels, suggesting the utility of these agents as a potential therapy for type 2 diabetes. In this ...
Learn more about Bile Acid Sequestrant Drugs at Grand Strand Medical Center Many Nutrients - Supplementation Likely Helpful The bile acid sequestrant...
Bile Acid SequestrantsPatients with terminal ileal disease may not absorb bile acids normally, which can lead to secretory diarrhea in the colon. These patients may benefit from bile acid sequestrants... more
vytorin hexal billig kaufen. vytorin pflaster preis - vytorin online - pflaster vytorin preisvergleich: Apotheke Inc Medical Supplies in Sandusky, OH - Wellness.I get muscle cramps could this be a side effect of simvastatin 40 mg? Find answers now! No. 1 Questions & Answers Place. More questions about Health, Diet & Fitness.Erektion uveitis q10 vs lipitor can I switch from to simvastatin can you. And hiv meds medicamento para el colesterol kamagra jelly preisvergleich einnahme a de 40.Simvastatin Sandoz 40 mg filmomhulde tabletten is doeltreffend alleen of in combinatie met anionuitwisselaars zoals colestyramine en colestipol.Apotheke, Preisvergleich und Testberichte. Preisvergleich - Apotheke. Simvastatin Corax 40 mg - Filmtabletten - 100 ST Corax Darreichungsform: Filmtabletten.. 1 Package leaflet Simvastatin XXX 40 mg, film-coated tablets Simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains ...
This drug is not recommended for use with: dofetilide. Ask your doctor or pharmacist for more details. Inform your doctor about all the medicines you may use (both prescription and nonprescription), especially if you take: lithium, digoxin, oral drugs used for diabetes, aspirin, NSAIDs (e.g., ibuprofen, naproxen), fluconazole. If you take colestipol or cholestyramine for high cholesterol, take the diuretic 1 hour before or 4 hours after because of decreased absorption into the bloodstream. Avoid any drugs that increase your heart rate or make you excited like decongestants because it may counter-act your blood pressure medicine. Decongestants are commonly found in over the counter cough-and-cold products. Ask your pharmacist if you are uncertain about decongestants in over-the-counter products. Do not start or stop any medicine without doctor or pharmacist approval. ...
Therapy Drug-drug interactions displayed by pressing [f3] while in the list of drugs will now display details of each interaction. The listings for drug toxicity and interactions have been extensively updated and expanded Drugs added Levofloxacin Pharmacological profile Ampicillin-sulbactam, Cefotetan, Doxycycline, Meningococcal vaccine, Ofloxacin, Pyrimethamine / sulfadoxine Susceptibility database Eubacterium lentum Testing criteria Levofloxaxin Interactions database Atorvastatin, Colestipol, Insulin, Molindone, Pirenzepine, Zalcitabine Microbiology Note: A variety of fermentation and other reactions for gram-positive bacilli and non-fermentative gram-negative bacilli may require three or more days. The GIDEON data base allows for delayed positivity in such cases. Therefore, do not indicate a negative response for such organisms until at least three days have passed (see individual notes [F2] in the identification module). New taxa added Achromobacter group B, Achromobacter group E, ...
Many studies have demonstrated that progression of atherosclerosis can be suppressed by reduction of serum cholesterol levels. In these studies, however, histopathological changes of the atherosclerotic lesions have not been sufficiently examined. Results of our study show that a reduction of serum cholesterol levels due to pravastatin treatment altered the lesional composition of atherosclerotic plaques in WHHL rabbits.. In the present study we showed that a long-term reduction of serum cholesterol levels led to the following histopathological changes in the atherosclerotic plaques: (1) a decrease in the area of macrophages plus extracellular lipid deposits, (2) an increase in collagen area, (3) a suppression of the decrease in smooth muscle cell area with lesion progress, and (4) an increase in the ratio of collagen area to the area of extracellular lipid deposits (Tables 3⇑ and 5⇑).. In recent human studies, several groups reported on acute clinical coronary events. Becker and coworkers ...
In Section 4.5 (Interactions) - Replacement of statement regarding interaction with cholestyramine with statement regarding interaction with bile acid sequestrants "such as cholestyramine". - In Section 4.6 (Fertility, pregnancy and lactation) - Re-wording and addition of statement regarding a pre-clinical study.. - In Section 4.8 (Undesirable effects) - Deletion of list of symptoms of hypercalcaemia. Deletion of frequency number definitions from tabulation.. - Minor clarifications and re-wordings in sections 2, 4.2, 4.4 and 6.6 ...
... often include statins or other cholesterol medicines. This eMedTV article lists various types of statins and other classes of cholesterol medications, such as bile acid sequestrants, fibrates, and niacin.
Drugs to reduce cholesterol and other lipids in blood. Classes of drugs used for this purpose include statins, bile acid sequestrants, nicotinic acid, and fibrates.
Some anti-seizure medicines and bile acid sequestrants can react negatively with L-methylfolate. This eMedTV resource outlines other negative L-methylfolate drug interactions and describes some of the complications these reactions can cause.
Purpose of review: Diagnostic scoring for familial hypercholesterolaemia (FH) can be used either to screen for possible FH or guide the selection of patients for genetic (DNA) testing. We review the published diagnostic criteria and discuss the options for future development. Recent findings: Scoring systems have been developed internationally based on lipid values and various combinations of clinical signs and cardiovascular history. The predictive value varies according to the test population, be it lipid clinic referrals, general population, or relatives of patients with FH. Also, there is increasing recognition of genetic heterogeneity in FH so that criteria are of differing predictive value depending on the genetic variant of FH. Summary: These clinical scoring systems are increasingly used to guide selection of patients for FH genetic testing but no single approach has yet emerged as the system of choice. Further refinement of these scoring tools using more sophisticated calculators are ...
Pharmacology and key clinical studies of Lojuxta (lomitapide), a selective inhibitor of microsomal transfer protein (MTP) for homozygous familial hypercholesterolaemia.
TY - JOUR. T1 - Familial hypercholesterolaemia. AU - Nair, Devaki R.. AU - Sharifi, Mahtab. AU - Al-Rasadi, Khalid. PY - 2014. Y1 - 2014. N2 - Increased awareness and wider availability of guidance to treat familial hypercholesterolaemia will improve management of familial hypercholesterolaemia. New therapies, if they become available after appropriate outcome studies, will reduce LDL-C levels in both homozygous familial hypercholesterolaemia and severe heterozygous familial hypercholesterolaemia, thus reducing the risk for premature CHD.. AB - Increased awareness and wider availability of guidance to treat familial hypercholesterolaemia will improve management of familial hypercholesterolaemia. New therapies, if they become available after appropriate outcome studies, will reduce LDL-C levels in both homozygous familial hypercholesterolaemia and severe heterozygous familial hypercholesterolaemia, thus reducing the risk for premature CHD.. KW - Familial hypercholesterolaemia. KW - Guidelines for ...
Bile acid sequestrants and nicotinic acid have cholesterollowering properties. They may occasionally be useful alone or in combination with statin therapy. However, their side-effects limit wider application.. 8.8 Treatment directed at other components of the lipid profile. Whereas low levels of HDL-C and high levels of TG are undoubtedly associated with a higher cardiovascular disease risk, no currently available treatment directed at reversing these changes has been shown to significantly benefit cardiovascular outcome.. A high triglyceride level, particularly if ,10 mmol/l, can result in acute pancreatitis and should be treated without delay.. 9. Special circumstances. 9.1 Metabolic syndrome. The European Guidelines recognise the importance of identifying patients with the metabolic syndrome, who are at increased risk of cardiovascular disease. The presence of the syndrome approximately doubles the risk of cardiovascular disease. Lifestyle changes, particularly reducing body weight and ...
Evidence-based recommendations on identifying and managing familial hypercholesterolaemia (inherited high cholesterol) for adults and children
The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD ...
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Background: Use of drug-eluting stents has raised new concerns including delayed re-endothelialization and coronary hypercontraction (HC), which may result in coronary adverse events. We hypothesized that intensive lipid lowering therapy by pitavastatin, a new strong statin, may ameliorate HC after coronary stenting through inhibition of Rho-associated kinase (ROCK) that controls contractility in vascular smooth muscle and eNOS expression in vascular endothelium, and tested our hypothesis in the CONTRACTION study with a randomized controlled design.. Methods and Results: During Dec. 2007 through Dec. 2010, we recruited 113 patients who were planned to undergo follow-up coronary angiogram 6-9 month after percutaneous coronary stenting. In 73 subjects without restenosis, we examined coronary responses to intracoronary acetylcholine (5, 15, 50 μ g/artery) and found that 55 (75%) subjects exhibited coronary HC defined as ,50% angiographical contraction with one of angina pectoris, ischemic ECG ...
There are several alternatives to Advicor, including other statins or cholesterol medicines. As this eMedTV page explains, besides statins, other cholesterol medicines include fibrates, cholesterol absorption inhibitors, and bile acid sequestrants.
Results A total of 227 index cases had 1075 first-degree relatives, including 442 adults and 117 children aged , 18 years resident in Oxfordshire. We excluded 171 previously screened adults and 46 for other reasons. Among 225 eligible adult relatives, 28 responders (12%) planned to consult their general practitioner and 52 (23%) attended the clinic for testing. Parents of 113 children (97%) wanted them tested. The positive diagnostic rate was 29% (15/52) in adults and 32% (36/113) in children. Screening increased prevalence by 14.4%, from 0.58/1000 (95% confidence intervals [CI] 0.52-0.65) to 0.67/1000 (95% CI 0.60-0.73), representing 33.5% of predicted cases ...
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis. Roberto R. Giraldez, Robert P. Giugliano, Satishkumar Mohanavelu, Sabina A. Murphy, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald. We compared outcomes in 2,986 statin-naïve acute coronary syndrome patients randomized to atorvastatin 80 mg versus pravastatin 40 mg in the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) study, stratified by baseline low-density lipoprotein cholesterol (LDL-C) quartiles. The benefit of atorvastatin 80 mg progressively declined as baseline LDL-C decreased. In the lowest quartile (baseline LDL-C ≤92 mg/dl), the adjusted rates of the primary (hazard ratio: 0.93, 95% confidence interval: 0.69 to 1.25) and secondary (hazard ratio: ...
Colestyramine (INN) or cholestyramine (USAN) (trade names Questran, Questran Light, Cholybar, Olestyr) is a bile acid sequestrant, which binds bile in the gastrointestinal tract to prevent its reabsorption. It is a strong ion exchange resin, which means it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer. Colestyramine removes bile acids from the body by forming insoluble complexes with bile acids in the intestine, which are then excreted in the feces. As a result of this loss of bile acids, more plasma cholesterol is converted to bile acids in the liver to normalise levels. This conversion of cholesterol into bile acids lowers plasma cholesterol levels. Bile acid sequestrants such as colestyramine were first used to treat hypercholesterolemia, but since the introduction of statins, ...
This page on the eMedTV site describes in detail the problems that may occur when doxycycline is combined with barbiturates, bile acid sequestrants, birth control pills, bismuth subsalicylate, and other drugs.
Familial hypercholesterolaemia (FH) is the most common inherited metabolic condition, affecting about one in 200 people. As highlighted by the European Atherosclerosis Society (EAS) Consensus Panel, FH is seriously underdiagnosed and undertreated. This App, authored by members of the Panel, provides an important resource to tackle these issues. Detection, diagnosis, screening and management of FH are discussed, with emphasis on targeting children with FH to optimise benefit and reduce premature heart disease.. Supported by an Unrestricted Educational Grant from SANOFI and REGENERON. App for iPad and iPhone ...
by Seth J. Baum MD PCSK9 inhibitors are the most significant advance in the management of elevated cholesterol in the last 3 decades. These injectable medications are indisputably revolutionary: They.. read more ...
Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-modifying drug therapy for a child or young person should take into account: their age the age of onset of coronary heart disease within the family, and the presence of other cardiovascular risk factors, including their LDL-C concentration. ...
Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Feeling Hypercholesterolaemia while using Solupred? Hypercholesterolaemia Causes, Patient Concerns and Latest Treatments and Solupred Reports and Side Effects.
PubMed 27843692 EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Freiberger T, Abifadel M, Aguilar-Salinas CA, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Ceska R, Corral P et al. (2016) ...
Familial hypercholesterolaemia (FH) is a relatively common genetic disorder associated with high risk of coronary heart disease that is preventable by early diagnosis and treatment. In a previous article, we reviewed the evidence for clinical management, models of care and health economic evaluations. The present commentary emphasises that collective action is needed to strengthen our approaches to evidence-based care, including better diagnosis and access to effective therapies. We detail how contemporary innovations in inter-operable, web-based, open-source and secure registries can provide the supporting infrastructure to: (i) address a current gap in the flow of data for measuring the quality of healthcare; (ii) support basic research through provision of high-quality, de-identified aggregate data; (iii) enable equitable access to clinical trials; and (iv) support efforts to disseminate evidence for best practice and information for care services. We describe how these aspects of enabling ...
OBJECTIVES: Individuals with heterozygous familial hypercholesterolaemia (FH) are at high risk of developing cardiovascular disease (CVD). This risk can be substantially reduced with lifelong pharmacological and lifestyle treatment; however, research suggests adherence is poor. We synthesised the qualitative research to identify enablers and barriers to treatment adherence.. DESIGN: This study conducted a thematic synthesis of qualitative studies.. DATA SOURCES: MEDLINE, Embase, PsycINFO via OVID, Cochrane library and CINAHL databases and grey literature sources were searched through September 2018.. ELIGIBILITY CRITERIA: We included studies conducted in individuals with FH, and their family members, which reported primary qualitative data regarding their experiences of and beliefs about their condition and its treatment.. DATA EXTRACTION AND SYNTHESIS: Quality assessment was undertaken using the Critical Appraisal Skills Programme for qualitative studies. A thematic synthesis was conducted to ...
0102] In some aspects the ratio of the aminocarboxylate to the water conditioning polymer to the sequestrant is in a ratio of from about 1:1:1 to about 5:1:10, preferably from about 1:1:1 to about 2.5:1:5. In some aspects the ratio of the aminocarboxylate to the water conditioning polymer is from about 1:5 to about 5:1, preferably from about 1:3 to about 3:1, preferably from about 1:2.5 to about 2.5:1, preferably from about 1:2 to about 2:1, or about 1:1. In a preferred aspect, the ratio of the aminocarboxylate to the water conditioning polymer is about 2:1. In some aspects the ratio of the aminocarboxylate to the sequestrant is from about 1:10 to about 10:1, preferably from about 1:5 to about 5:1, preferably from about 1:3 to about 3:1, preferably from about 1:2 to about 2:1, or about 1:1. In some aspects the ratio of the water conditioning agent to the sequestrant is from about 1:10 to about 10:1, preferably from about 1:5 to about 5:1, preferably from about 1:3 to about 3:1, preferably from ...

Colestipol: MedlinePlus Drug InformationColestipol: MedlinePlus Drug Information

Colestipol: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking colestipol,. *tell your doctor and pharmacist if you are allergic to colestipol, any other medications, or any of ... Continue to take colestipol even if you feel well. Do not stop taking colestipol without talking to your doctor. ... Take colestipol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ...
more infohttps://medlineplus.gov/druginfo/meds/a682157.html

Colestipol Side Effects in Detail - Drugs.comColestipol Side Effects in Detail - Drugs.com

Learn about the potential side effects of colestipol. Includes common and rare side effects information for consumers and ... Applies to colestipol: oral powder for suspension, oral tablet. Along with its needed effects, colestipol may cause some ... Applies to colestipol: oral granule for reconstitution, oral tablet. General. The most frequently reported side effects were ... Check with your doctor as soon as possible if any of the following side effects occur while taking colestipol:. More Common. * ...
more infohttps://www.drugs.com/sfx/colestipol-side-effects.html

PatientsLikeMe | Colestipol report for  patients like youPatientsLikeMe | Colestipol report for patients like you

Find the most comprehensive real-world treatment information on Colestipol at PatientsLikeMe. 15 patients with fibromyalgia, ... bipolar I disorder or psoriasis currently take Colestipol. ... Currently taking Colestipol Duration. Patients. This item is ... Most popular types: Colestipol Suspension Colestid Flavored false Colestipol is a cholesterol-lowering drug. It is used as an ... Stopped taking Colestipol Duration. Patients. This item is relevant to you: 1 - 6 months 1 * 1 ...
more infohttps://www.patientslikeme.com/treatments/show/2339-colestipol-suspension-side-effects-and-efficacy

Colestipol (Oral Route) Description and Brand Names - Mayo ClinicColestipol (Oral Route) Description and Brand Names - Mayo Clinic

Colestipol works by attaching to certain substances in the intestine. Since colestipol is not absorbed into the body, these ... Colestipol is used to lower high cholesterol levels in the blood. This may help prevent medical problems caused by cholesterol ... Colestipol may also be used for other conditions as determined by your doctor. ...
more infohttps://www.mayoclinic.org/drugs-supplements/colestipol-oral-route/description/drg-20068621

Interactions between Candesartan-Hydrochlorothiazide Oral and thiazide-related-diuretics-cholestyramine-colestipolInteractions between Candesartan-Hydrochlorothiazide Oral and thiazide-related-diuretics-cholestyramine-colestipol

... about interactions between Candesartan-Hydrochlorothiazide Oral and thiazide-related-diuretics-cholestyramine-colestipol. ... Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. Clin Pharmacol Ther 1973 Sep-Oct; 14(5):886-90. ... 4.Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int ... Thiazide & Related Diuretics/Cholestyramine; Colestipol. This information is generalized and not intended as specific medical ...
more infohttps://www.webmd.com/drugs/2/drug-19953/candesartan-hydrochlorothiazide-oral/details/list-interaction-details/dmid-81/dmtitle-thiazide-related-diuretics-cholestyramine-colestipol/intrtype-drug

Colestipol - WikipediaColestipol - Wikipedia

ISBN 3-8047-1763-2. Clinical Pharmacology: Colestipol structure Beth Israel Deaconess Medical Center & Care Group: Colestipol ... Colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood).[citation needed] Colestipol ... Like cholestyramine, colestipol works in the gut by trapping bile acids and preventing them from being reabsorbed. This leads ... Colestipol (trade names Colestid, Cholestabyl) is a bile acid sequestrant used to lower blood cholesterol, specifically low- ...
more infohttps://en.wikipedia.org/wiki/Colestipol

Colestipol granules for oral suspension - AHealthyMe - Blue Cross Blue Shield of MassachusettsColestipol granules for oral suspension - AHealthyMe - Blue Cross Blue Shield of Massachusetts

Colestipol granules for oral suspension. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
more infohttp://www.ahealthyme.com/Library/DiseasesConditions/Adult/Digestive/121,996

COLESTID (Colestipol) dosage, indication, interactions, side effects | EMPR - ONACOLESTID (Colestipol) dosage, indication, interactions, side effects | EMPR - ONA

Colestipol) drug information & product resources from MPR including dosage information, educational materials, & patient ... Colestipol HCl 5g/pkt or scoop; granules; orange flavored (contains aspartame, phenylalanine) or unflavored. ...
more infohttps://www.oncologynurseadvisor.com/colestid/drug/263/

Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia | Annals of Internal Medicine |...Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia | Annals of Internal Medicine |...

5 g of cellulose placebo; 5 g of colestipol; 2.5 g of colestipol plus 2.5 g of psyllium; or 5 g of psyllium three times daily ... Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia J. David Spence, MD; Murray W. Huff ... A combination of 2.5 g of psyllium and 2.5 g of colestipol was better tolerated than and as effective as either 5 g of ... Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia. Ann Intern Med. ;123:493-499. doi: ...
more infohttp://annals.org/aim/article-abstract/709076/combination-therapy-colestipol-psyllium-mucilloid-patients-hyperlipidemia

Colestipol and Probucol: Treatment of Primary and Familial Hypercholesterolemia and Amelioration of Atherosclerosis | Annals of...Colestipol and Probucol: Treatment of Primary and Familial Hypercholesterolemia and Amelioration of Atherosclerosis | Annals of...

Probucol with Colestipol in the Treatment of Hypercholesterolemia Annals of Internal Medicine; 100 (4): 477-482 ... Colestipol and Probucol: Treatment of Primary and Familial Hypercholesterolemia and Amelioration of Atherosclerosis CHARLES J. ... Long-term colestipol therapy in conjunction with diet may reduce xanthoma size, arrest progression of coronary artery ... Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia Annals of Internal ...
more infohttps://annals.org/aim/article-abstract/695483/colestipol-probucol-treatment-primary-familial-hypercholesterolemia-amelioration-atherosclerosis

Colestid (Colestipol) Basics, Side Effects & Reviews - Iodine.comColestid (Colestipol) Basics, Side Effects & Reviews - Iodine.com

Colestipol); from expert pharmacists and people like you ... Colestid (Colestipol). 0 reports. These are side effects of. ... colestipol. at all.. *Percentages only tell you how common an issue is for people who actually make the effort to report side ... Colestid (Colestipol). questions for. Select an indication to see answers for that use case. Hyperlipidemia. ... Colestid (Colestipol) reported to the FDA by people taking it, and by doctors and pharmacists. ...
more infohttps://www.iodine.com/drug/colestid

1990 - Niacin and lovastatin were more efficient than gemfibrozil, probucol, colestipol,
         or cholestyramine for...1990 - Niacin and lovastatin were more efficient than gemfibrozil, probucol, colestipol, or cholestyramine for...

To determine the relative cost-effectiveness of lowering high blood cholesterol with cholestyramine, colestipol, gemfibrozil, ... Niacin and lovastatin were more efficient than gemfibrozil, probucol, colestipol, or cholestyramine for lowering cardiovascular ... Patients received monotherapy with cholestyramine, colestipol, niacin, gemfibrozil, lovastatin, or probucol compared with ... colestipol, or cholestyramine for lowering cardiovascular risk among patients with type II hyperlipoproteinemia and total ...
more infohttp://acpjc.org/Content/114/3/issue/ACPJC-1991-114-3-093.htm

Colestipol  | YourCareEverywhereColestipol | YourCareEverywhere

Colestipol Hydrochloride Oral suspension. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... Colestipol Hydrochloride Oral tablet. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... Colestipol Hydrochloride, Micronized Oral tablet. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
more infohttps://www.yourcareeverywhere.com/article/krames/en/article/health-research/drugs-and-supplements/drug-search/colestipol.html

JoVE Search Results: ColestipolJoVE Search Results: Colestipol

Alteration of aluminium inhibition of synaptosomal (Na(+)/K(+))ATPase by colestipol administration. Abstract ...
more infohttp://labindex.jove.com/group/Colestipol

Order Colistop Online - Colestipol DosageOrder Colistop Online - Colestipol Dosage

colestipol side effects diagn ib. the duration of the paroxysms the occurrence of intermis ... Colestipol drug: offset bv the observation of those who have been most. ... Colestipol Mechanism Of Action. admin 0 Comment colestipol mechanism of action colestipol dosage attended with stupefaction ... e y electricity colestipol drug colestipol uses When they are intimately mixed with the urine in such a way that ...
more infohttp://guildwars2forum.com/colestipol-mechanism-of-action/

Colestipol Hydrochloride Side Effects - DrugInformerColestipol Hydrochloride Side Effects - DrugInformer

View full report on Colestipol Hydrochloride related fatigue Did the author experience fatigue while taking colestipol ... View full report on Colestipol Hydrochloride related alopecia Did the author experience alopecia while taking colestipol ... Colestipol Hydrochloride Side Effects. Filter Table by Serious Outcome. ×. Filter by Serious Outcome. ... View full report on Colestipol Hydrochloride related confusional state Did the author experience confusional state while taking ...
more infohttps://druginformer.com/search/side_effect/flavored+colestid

Colestipol-Niacin Therapy and Coronary Atherosclerosis | JAMA | JAMA NetworkColestipol-Niacin Therapy and Coronary Atherosclerosis | JAMA | JAMA Network

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts, ... Colestipol-Niacin Therapy and Coronary Atherosclerosis. JAMA. 1987;258(19):2694. doi:10.1001/jama.1987.03400190076017 ... To the Editor.- In the article entitled "Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis ...
more infohttps://jamanetwork.com/journals/jama/article-abstract/369259

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. - AdisInsightA Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. - AdisInsight

Drugs Colestipol (Primary) ; Ezetimibe (Primary) ; Niacin (Primary) ; HMG-CoA reductase inhibitors * Indications ... A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. Next Previous ... A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. Completed ...
more infohttps://adisinsight.springer.com/trials/700007112?error=cookies_not_supported&code=1246f649-ccf8-4386-b021-f984e17da1e7

Which medications in the drug class Bile Acid Sequestrants are used in the treatment of Crohn Disease?Which medications in the drug class Bile Acid Sequestrants are used in the treatment of Crohn Disease?

Colestipol (Colestid). Colestipol forms a soluble complex after binding to bile acid, increasing fecal loss of bile acid-bound ... These patients may benefit from bile acid sequestrants such as cholestyramine and colestipol. ...
more infohttps://www.medscape.com/answers/172940-18379/937574-overview

Aliskiren/hydrochlorothiazide | Side Effects, Dosage & MoreAliskiren/hydrochlorothiazide | Side Effects, Dosage & More

colestipol. Pain drugs. These drugs may decrease the effects of aliskiren/hydrochlorothiazide. This means that it may not work ...
more infohttps://www.healthline.com/drugs/aliskiren-hydrochlorothiazide/oral-tablet

Amlodipine/Valsartan/Hydrochlorothiazide | Side Effects & MoreAmlodipine/Valsartan/Hydrochlorothiazide | Side Effects & More

colestipol. Depression drugs. Fluoxetine increases the amount of amlodipine/valsartan/hydrochlorothiazide in your body. This ...
more infohttps://www.healthline.com/drugs/amlodipine-hydrochlorothiazide-valsartan/oral-tablet

Crohn Disease Medication: 5-Aminosalicylic Acid Derivatives, Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Alpha...Crohn Disease Medication: 5-Aminosalicylic Acid Derivatives, Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Alpha...

Colestipol forms a soluble complex after binding to bile acid, increasing fecal loss of bile acid-bound low-density lipoprotein ... These patients may benefit from bile acid sequestrants such as cholestyramine (2-4 g) and colestipol (5 g 2 or 3 times daily ... These patients may benefit from bile acid sequestrants such as cholestyramine and colestipol. ...
more infohttps://emedicine.medscape.com/article/172940-medication

Micardis HCT - FDA prescribing information, side effects and usesMicardis HCT - FDA prescribing information, side effects and uses

Cholestyramine and Colestipol Resins. Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins ... certain cholesterol lowering medicines (resins that are used for cholesterol reduction, e.g.,cholestyramine and colestipol ...
more infohttps://www.drugs.com/pro/micardis-hct.html

Avalide (Irbesartan-Hydrochlorothiazide): Side Effects, Interactions, Warning, Dosage & UsesAvalide (Irbesartan-Hydrochlorothiazide): Side Effects, Interactions, Warning, Dosage & Uses

Cholestyramine And Colestipol Resins. Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins ...
more infohttps://www.rxlist.com/avalide-drug.htm

Cholesterol Drugs: What to Expect With Heart MedicationCholesterol Drugs: What to Expect With Heart Medication

Prescribed for: Colestipol (Colestid) is used for the treatment of high cholesterol in conjunction with dietary control; for ... colestipol (Colestid). Drug Class: Bile acid sequestrants. Prescription: Yes. Generic: Yes. Preparations: Tablet of 1 gm. ... Side effects: Side effects of colestipol (Colestid) include constipation, stomach upset, heartburn, indigestion, belching, gas ...
more infohttps://www.emedicinehealth.com/slideshow_cholesterol_drugs/article_em.htm
  • FDA Label, F4555, F4567, LAnd even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as. (drugbank.ca)
  • In the article entitled "Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts," Blankenhorn et al 1 presented exciting data concerning the possible stabilization of and improvement in coronary lesions in patients with a previous history of coronary bypass grafting who were treated with diet and cholesterol-reducing drugs. (jamanetwork.com)
  • A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. (springer.com)
  • colestipol mechanism of action colestipol dosage attended with stupefaction caused by blows on the head which cases and added the following and wishes to emphasize that traces or it may be absent altogether glomerular atrophy especially in colestipol side effects is more efficient or common than the abuse of intoxicating drinks. (guildwars2forum.com)
  • Unless otherwise instructed, take all other medications at least 1 hour before or 4 hours after you take colestipol because it can interfere with their absorption. (medlineplus.gov)
  • Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. (webmd.com)
  • The following notable side effects may occur: gastrointestinal tract disturbances, especially (mild, occasionally severe) constipation sometimes increase in VLDL[citation needed] and triglyceride synthesis Colestipol can bind to a number of drugs and nutrients in the gut and inhibit or delay their absorption. (wikipedia.org)
  • Colestipol may decrease your absorption of other medications. (kaiserpermanente.org)
  • Colestipol is in a class of medications called bile acid sequestrants. (medlineplus.gov)
  • Colestipol forms a soluble complex after binding to bile acid, increasing fecal loss of bile acid-bound low-density lipoprotein cholesterol. (medscape.com)
  • These patients may benefit from bile acid sequestrants such as cholestyramine (2-4 g) and colestipol (5 g 2 or 3 times daily before meals). (medscape.com)
  • Bile acid sequestrants like colestipol have been in use since the 1970s. (drugbank.ca)
  • To test whether combining psyllium mucilloid with half the usual dose of colestipol reduces the adverse effects associated with colestipol and maintains or increases its efficacy in the treatment of hyperlipidemia. (annals.org)
  • If you become pregnant while taking colestipol, call your doctor. (medlineplus.gov)
  • Along with its needed effects, colestipol may cause some unwanted effects. (drugs.com)
  • Do not stop taking colestipol without talking to your doctor. (medlineplus.gov)
  • Colestipol may also be used for other conditions as determined by your doctor. (mayoclinic.org)
  • Clinical Pharmacology: Colestipol structure Beth Israel Deaconess Medical Center & Care Group: Colestipol structure Archived 2010-12-29 at the Wayback Machine. (wikipedia.org)
  • Since colestipol is not absorbed into the body, these substances also pass out of the body without being absorbed. (mayoclinic.org)